Mason Freeman - Profile and Investment Details

Investor Profile

Mason Freeman is a Venture Capital, Investor based in Boston, Massachusetts, United States with a diverse investment portfolio that includes companies such as Precision NanoSystem, Vor Biopharma, Aprea, Arvinas, GenePeeks, RareCyte, Portal Instruments, Entrada Therapeutics, Ceterix OrthopaedicsAudentes Therapeutics, CinCor Pharma, Homology Medicines, Cabaletta Bio, Flexion Therapeutics, Expansion Therapeutics, Spyryx Biosciences, Ensoma, Cleave Therapeutics, Nohla Therapeutics, scPharmaceuticals, Wildcat Discovery Technologies, Scientist.com, Relypsa, Purigen Biosystems, Epirus Biopharmaceuticals, Rallybio, Pulmatrix, Crinetics Pharmaceuticals, NodThera, Kinaset Therapeutics, Calibrium, Inipharm, Kinestral Technologies, Magnetic Insight, TMRW Life Sciences, Pearl Therapeutics, Chrono Therapeutics, Impel NeuroPharma, Igenica, Nouscom, Novira Therapeutics, Bird Rock Bio, Viveve, Enliven Therapeutics, Millendo Therapeutics, Pear Therapeutics, Achaogen, Escient Pharmaceuticals, Artiva Biotherapeutics, Cidara Therapeutics, Akouos, Bellerophon Therapeutics, IDEAYA Biosciences, BlueLight Therapeutics, Neurogastrx, Novome Biotechnologies, . Over time, Mason Freeman has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Mason Freeman is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Patient Care, Health Care, Hospitals, Genetics, Healthcare Delivery, Wellness, Healthcare Innovation, Telemedicine, Life Science, Medical Technologies, Education, Software, Biotechnology, Genomics, Neuroscience, Clinical Trials, Research, Telehealth, Digital Health, Medical, Therapeutics, Emergency Medicine, Pharmaceuticals, Healthcare Technology may find it worthwhile to explore potential connections with Mason Freeman, as their portfolio suggests a familiarity and interest in this area.

Understanding Mason Freeman’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.